Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities (Pharmaceutical Business Review)

Introduction Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion.

[News Source]


   Posted in Lyrica